Invesco Ltd. decreased its stake in Heska Corp (NASDAQ:HSKA) by 21.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,074 shares of the medical research company’s stock after selling 16,636 shares during the period. Invesco Ltd. owned about 0.77% of Heska worth $5,117,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of HSKA. Financial Gravity Wealth Inc. bought a new position in shares of Heska during the second quarter valued at $29,000. Aperio Group LLC bought a new position in shares of Heska during the second quarter valued at $79,000. Quantamental Technologies LLC bought a new position in shares of Heska during the second quarter valued at $120,000. Bank of Montreal Can raised its stake in shares of Heska by 30.3% during the second quarter. Bank of Montreal Can now owns 2,162 shares of the medical research company’s stock valued at $183,000 after acquiring an additional 503 shares during the last quarter. Finally, Everence Capital Management Inc. bought a new position in shares of Heska during the second quarter valued at $245,000. 89.02% of the stock is owned by institutional investors and hedge funds.
HSKA has been the subject of several analyst reports. Canaccord Genuity dropped their price target on shares of Heska from $95.00 to $75.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. ValuEngine raised shares of Heska from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Piper Jaffray Companies initiated coverage on shares of Heska in a research note on Wednesday, September 18th. They set a “neutral” rating and a $68.00 price target for the company. Finally, BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a research note on Wednesday, September 18th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $85.25.
Heska (NASDAQ:HSKA) last announced its earnings results on Tuesday, August 6th. The medical research company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. Heska had a net margin of 1.93% and a return on equity of 6.35%. The business had revenue of $28.15 million during the quarter, compared to the consensus estimate of $29.19 million. As a group, equities analysts expect that Heska Corp will post 0.04 earnings per share for the current fiscal year.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Recommended Story: Stop Order Uses For Individual Investors
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.